SCHEMBL21995249

SCHEMBL21995249

Cc1ccc(S(=O)(=O)CC#N)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 1/20 0.42
RAPGEF4 Q8WZA2 1/20 0.41
ALDH1A1 P00352 6/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.41
ALOX12 P18054 1/20 0.41
GFER P55789 1/20 0.41
KMT2A Q03164 2/20 0.40
HSD17B10 Q99714 1/20 0.39
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
GAA P10253 1/20 0.39
MEN1 O00255 1/20 0.38
MAP1LC3B Q9GZQ8 1/20 0.38
KDM4E B2RXH2 1/20 0.38
F2 P00734 1/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30773057 1.00 MEP1B (0.42) MEP1BRAPGEF4ALDH1A1MAPTHPGD
SCHEMBL21995280 0.83 GAA (0.43) ALDH1A1MAPTKMT2AGAAMEN1
SCHEMBL17376378 0.83 TSHR (0.44) MEP1BALDH1A1KMT2ALMNAMEN1
SCHEMBL17376428 0.83 KAT6A (0.38) MEP1BHPGDKMT2ALMNASMN1; SMN2
SCHEMBL22057010 0.83 CA1 (0.46) ALDH1A1SMN1; SMN2GLA
SCHEMBL22057011 0.83 GLA (0.36) MEP1BALDH1A1KMT2ALMNAMEN1
SCHEMBL22056787 0.83 GABRA1 (0.37) ALDH1A1HPGDGAAKDM4EGLA
SCHEMBL22056798 0.83 TRPV4 (0.43) ALDH1A1MAPT
SCHEMBL31514033 0.83 GAA (0.43) ALDH1A1MAPTKMT2AGAAMEN1
SCHEMBL24218705 0.81 MEN1 (0.38) RAPGEF4ALDH1A1MAPTHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509462-B2 3-(phenylsulfonyl)-[1,2,3]triazolo[1,5A]quinazolin-5(4H)-one derivatives BioVersys AG (CH) 2025-12-30 US disclosed
EP-3887375-B1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2024-11-20 EP disclosed
US-20220024928-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2022-01-27 US disclosed
US-20220024928-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2022-01-27 US disclosed
EP-3887375-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES Bioversys AG (CH) 2021-10-06 EP disclosed
WO-2020109350-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2020-06-04 WO disclosed
WO-2020109350-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES BioVersys AG (CH) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024928-A1 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES OR10J3, ORC3, CBR3 MEP1B 3781/4885RAPGEF4 4209/4885ALDH1A1 1547/4885
US-12509462-B2 3-(phenylsulfonyl)-[1,2,3]triazolo[1,5A]quinazolin-5(4H)-one derivatives CUTA, OR10J3, CCR10 MEP1B 4174/4885RAPGEF4 4738/4885ALDH1A1 1420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.